The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...
AbbVie, Danaher, Organovo, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of ...
Discover eight promising respiratory disease companies advancing their novel therapies through clinical trials in 2025.
Vertex Pharmaceuticals EVP Edward Atkinson sold 1,767 shares for $849,838 on Feb. 25, 2025. This transaction, conducted under ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...
Vertex Pharmaceuticals exits liver disease gene editing program with Verve Therapeutics. Verve continues work on a separate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results